Table of Contents: CATIE News - 2003
Canadian AIDS Treatment Information Exchange
Edited by: Alan Boutilier and Sean Hosein

Table Of Contents

December
Stem-cell transplants help beat lymphoma; Adherence support found cost-effective; Large study links adherence to survival; More fat loss than fat gain in HIV positive women; First once-daily protease inhibitor approved in Canada
November
HIV vaccine fails again; Can fibre help fight fat gain?
October
Tenofovir - Caution needed with some combinations; T-20 (Fuzeon) goes on sale in Canada
September
Once-daily 3TC approved in Canada; Small but increasing risk of cardiac surgery seen in HAART-users in British Columbia
August
Important changes made to American HIV treatment guidelines; HIV drug resistance appears in newly positive people in Europe; Hepatitis C found to diminish response to HAART; Intensifying calcium dose helps fix nelfinavir-related diarrhea; Rising STD rates may herald an increase in transmission of HIV and drug-resistant HIV
July
First once-daily protease inhibitor approved in the U.S.; Americans approve once-daily nuke for HIV; French doctors suggest that therapy switch may cause KS relapse; New guidelines for caring for HIV+ pregnant women; New guidelines available for HIV drug resistance testing
June
New drug being studied for lipodystrophy;
May
Fewer pills of nelfinavir on the way; Finding and fixing nerve problems may improve quality of life; A nuke-free regimen found effective
April
The 12th Annual Canadian Conference on HIV/AIDS Research; Tenofovir side effects; The Work of Adherence; Starting Therapy and Adherence — Moving beyond pill boxes and timers; Calcium supplements for drug-related diarrhea
March
10th Conference on Retroviruses and Opportunistic Infections: New drugs in the pipeline; Americans approve new type of drug for HIV: T20; Protease inhibitors can increase the risk of diabetes in women; New website for information on herbs and supplements; New drug approved in Canada — tenofovir
February
Lung cancer in HIV positive HAART-users; Study finds nevirapine as effective as efavirenz; Controversial HIV vaccine trial results disappointing
January
Antibody therapy zaps cancer; Can you fight heart disease with fish?
Copyright / Funding / How to reach CATIE
ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980,2003. ÆGiS . All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS , or the party credited as the provider of the content. Please contact the party credited as the provider of the content for permission to reproduce.